Viral vectors as vaccine platforms: from immunogenicity to impact.
Viral vectors are the vaccine platform of choice for many pathogens that have thwarted efforts towards control using conventional vaccine approaches. Although the STEP trial encumbered development of recombinant human adenovirus vectors only a few years ago, replication-deficient simian adenoviruses have since emerged as a crucial component of clinically effective prime-boost regimens. The vectors discussed here elicit functionally relevant cellular and humoral immune responses, at extremes of age and in diverse populations. The recent Ebola virus outbreak highlighted the utility of viral vectored vaccines in facilitating a rapid response to public health emergencies. Meanwhile, technological advances in manufacturing to support scale-up of viral vectored vaccines have helped to consolidate their position as a leading approach to tackling 'old' and emerging infections.
The Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.
Katie J
KJ
Ewer
The Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.
Teresa
T
Lambe
Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford OX3 7LJ, UK; Oxford NIHR Biomedical Research Centre, University of Oxford, UK.
Christine S
CS
Rollier
The Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.
Alexandra J
AJ
Spencer
The Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK; Oxford NIHR Biomedical Research Centre, University of Oxford, UK.
Adrian Vs
AV
Hill
Oxford NIHR Biomedical Research Centre, University of Oxford, UK; Nuffield Department of Medicine, University of Oxford, Oxford OX3 7FZ, UK. Electronic address: lucy.dorrell@ndm.ox.ac.uk.
Lucy
L
Dorrell
D000818:Animals; D005822:Genetic Vectors / Q000235:genetics*; D006801:Humans; D000071497:Immunogenicity, Vaccine / Q000235:genetics* / Q000276:immunology*; D014765:Viral Vaccines / Q000235:genetics* / Q000276:immunology*
D014765:Viral Vaccines